Streetwise Reports' Article Archives — May 2020 back to current month (36)
Patriot One Technologies and its partners have created a model that automatically calculates, from a radiological scan, the degree of a patient's affected lungs, a COVID-19 indicator.
Algernon Pharmaceuticals is quickly moving ahead with a multinational Phase 2b/3 trial for Ifenprodil.
Imagin Medical delivered two functional i/Blue™ Imaging Systems for use in conducting in vivo studies and virtual demonstrations for evaluation by leading urologists.
Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report.
The goal of Sorrento Therapeutics to develop a Covid-19 antibody cocktail, including its progress, next steps and market opportunity, is reviewed in a Dawson James report.
Shares of Mersana Therapeutics reached a new 52-week high price after the company reported positive interim data from the expanded portion of its Phase 1 study of XMT-1536 for treatment of ovarian cancer.
Novavax shares traded higher after the company reported it enrolled the first participants in its Phase 1 clinical study of NVX CoV2373.
With CBD showing some promise against Covid-19 and cannabis stocks rising, Peter Epstein of Epstein Research discusses the market with Sweet Earth Holdings executives.
With this sale, Avivagen's antibiotics-free, immune-boosting feed additive enters the Mexican market.
With its work on this and a SARS-CoV-2 test, ProMIS Neurosciences is applying its technology platform in new ways.
Shares of Surface Oncology set a new 52-week high price after the company reported that it is partnering with Merck & Co. in an immuno-oncology study of SRF617, targeting CD39 in combination with KEYTRUDA® (pembrolizumab) in solid tumor patients.
Daré Bioscience's study, its prospects and the indication's U.S. market opportunity are discussed in a ROTH Capital Partners report.
Shares of Arbutus Biopharma traded higher after the company reported significant and continuous reduction in HBsAg in 12 chronic hepatitis B subjects using 60 mg dosage of its AB-729 drug.
Imagin Medical reported that its actions have mitigated the impact of the coronavirus on its business operations.
Shares of Moderna Inc. traded higher, setting a new 52-week high price, after the firm reported positive interim results in its Phase 1 study of mRNA Vaccine (mRNA-1273) against SARS-CoV-2.
Algernon Pharmaceuticals intends to test a repurposed drug for this indication, in a trial in three countries.
Sproutly Canada has received capital investment from Infusion Biosciences.
Shares of Aurora Cannabis traded 60% higher after the company reported an 18% rise in net revenue, which included a 24% increase in consumer sales versus to the prior quarter.
ProMIS Neurosciences advances its various antibody programs related to neurodegenerative diseases and viral infections such as Covid-19.
Shares of Allogene Therapeutics traded higher and reached a new 52-week high price after the company reported initial results from its Phase 1 relapsed/refractory non-Hodgkin lymphoma trial.
The development timeline for Inovio Pharmaceuticals' coronavirus vaccine candidate is discussed in an H.C. Wainwright & Co. report.
Testing and validation of ProMIS Neurosciences' antibody targets will be conducted over the coming weeks.
Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy.
Algernon Pharmaceuticals reported that it has received ethics approval in Australia for a Phase 2 human clinical study of NP-120 (Ifenprodil) for use in treatment of idiopathic pulmonary fibrosis and chronic cough.
Shares of Protagonist Therapeutics traded higher and reached a new 52-week high price after the company released Q1/20 financial results and positive data from its Phase 2 study of PTG-300 in patients with polycythemia vera, a type of blood cancer.
This arrangement will bolster the use of CloudMD Software & Services' software in the United States.
Building a Better Covid-19 Antibody Test (05/06/2020)
ProMIS is harnessing its unique technology platform to develop a more error-free antibody test.
Arcturus Therapeutics Holdings' arrangement is explained and commented on in an H.C. Wainwright & Co. report.
ProMIS Neurosciences' antagonists prevent dysfunctional protein aggregation.
Shares of Horizon Therapeutics traded higher setting a new 52-week high price after the company reported a 27% y-o-y increase in net sales for Q1/20 and raised FY/20 net sales guidance.
CloudMD announced that it is partnering with Save-On-Foods grocery stores and Pure Integrative Pharmacy to pilot on demand, integrated virtual patient care through telemedicine kiosks placed in pharmacies' existing consult rooms.
Shares of Portola Pharmaceuticals traded 130% higher after the company reported that it has received an $18 per share buyout offer from Alexion Pharmaceuticals.
Use of CloudMD Software & Services' health solution is seeing significant growth.
ProMIS Neurosciences reported it has generated novel intrabodies that are highly selective for misfolded forms of TAR DNA-binding protein 43 implicated in several neurologic disorders.
Shares of Stemline Therapeutics traded 150% higher after the company reported that it has entered into a definitive agreement to be acquired by Italy's Menarini Group in a deal valued at up to $677 million.
Seattle Genetics shares traded 8% higher, reaching a new 52-week high, after the company reported Q1/20 financial results which included a 10% y-o-y increase in net revenues fueled by a 22% increase in sales of ADCETRIS® and a strong debut for PADCEV™ in its first full quarter of sales.
|"PMN's upside is relatively unlimited; it is rated an Immediate Buy."|